Kejun Liu

5PUBLICATIONS
0CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 01, 2026
Initial Low-Dose Dacomitinib for First-Line Treatment of Patients With EGFR Exon 21-Mutated Non-Small-Cell Lung Cancer.

|Dec 16, 2025
Comparing the effect of traditional and novel tyrosine kinase inhibitors for epidermal growth factor receptor exon 20 insertions by molecular dynamics simulation.

Ke-Jun Liu, Tao Jiang, Quan-Quan Tan

|Mar 19, 2025
The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysis.

Ke-Jun Liu, Hong-Rui Li, Quan-Quan Tan

|Dec 22, 2020
Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer.

Kejun Liu, Guanming Jiang, Nianxin Fang

|Feb 01, 2020
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.

Kejun Liu, Guanming Jiang, Ailing Zhang

Pageof 1

Frequent Collaborators